9 Results for "

H1993

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "H1993" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-13299
CAS No.: 1001917-37-8
Purity:  98.34%
Target:  

c-Met/HGFR

Research Areas:  

Cancer

MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13299A
CAS No.: 1283000-43-0
Purity:  99.86%
Target:  

c-Met/HGFR

Research Areas:  

Cancer

MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .
loading...
    loading...
Cat. No.: HY-16446
CAS No.: 1116743-46-4
Research Areas:  

Cancer

SAR125844 is a potent, selective, and ATP-competitive MET kinase inhibitor with the value of IC50 is 4.2 nM and Ki is 2.8 nM. SAR125844 has antitumor activity and can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-164384
CAS No.: 2125500-60-7
Target:  

PI3K Akt mTOR Apoptosis

Research Areas:  

Cancer

DFX117 is a selective, orally active inhibitor for PI3Kα and c-Met tyrosine kinase. DFX117 inhibits PI3K/Akt/mTOR pathway, inhibits the proliferation of NCI-H1975, NCI-H1993, and HCC827 with IC50s 0.02-0.08 µM. DFX117 arrests cell cycle at G0/G1 phase, induces apoptosis in A549 and NCI-H1975. DFX117 exhibits antitumor efficacy in mice .
loading...
    loading...
Cat. No.: HY-147040
CAS No.: 2242563-15-9
Purity:  99.19%
Target:  

c-Met/HGFR Apoptosis

Research Areas:  

Cancer

ABN401 is an orally active and selective ATP-competitive c-MET inhibitor with an IC50 of 10 nM. ABN401 is cytotoxic to MET-addicted cancer cells with the IC50 of 2-43 nM. ABN401 has bioavailability in rats and dogs of 42.1-56.2% and 27.4-37.7%, respectively. ABN401 has antitumor activity .
loading...
    loading...
Cat. No.: HY-120387
CAS No.: 1253286-90-6
SMU-B is the orally active inhibitor for ALK (IC50<0.5 nM), c-ros oncogene 1 (ROS1), c-MET (IC50=1.87 nM) and AXL (IC50=28.9 nM). SMU-B inhibits the proliferation of MKN45, H1993 and H441 with IC50s of 0.02 μM, 1.58 μM and 2.82 μM, respectively. SMU-B exhibits antitumor efficacy in mouse models .
loading...
    loading...
Cat. No.: HY-180183
Research Areas:  

Cancer

DLG-41 is a GAS41 YEATS domain inhibitor (IC50: 600 nM in AlphaLISA). DLG-41 potently disrupts the association of GAS41 YEATS with chromatin in cells. DLG-41 strongly enhances levels of CDKN1A. DLG-41 has anticancer activity against NSCLC .
loading...
    loading...
Cat. No.: HY-165284
CAS No.: 1370652-56-4
Research Areas:  

Cancer

CM-118 is a potent and selective c-Met and ALK inhibitor. CM-118 inhibits the HGF-induced c-Met phosphorylation. CM-118 inhibits phosphorylation of ALK, EML4-ALKv1, ALK F1174L, and EMl4-ALKv1 L1196M, with respective IC50 values 0.92, 1.25, 1.9, and 3.5 μM. CM-118 exhibits anticancer activity against cancers dependent on the c-Met or ALK oncogenic pathways .
loading...
    loading...
Cat. No.: HY-168268
CAS No.: 1635406-97-1
Target:  

c-Met/HGFR

Research Areas:  

Cancer

c-Met-IN-26 (compound 1-170) is a potent inhibitor of c-Met, with the IC50 of 1.6 nM. c-Met-IN-26 palys an important role in cancer research .
loading...
    loading...